TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT05835466: Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)

Sponsor: Icahn School of Medicine at Mount Sinai · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 20 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$1,755,600

Rescue Site Savings

+$1,155,000

Unlock Full NCT05835466 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05835466 Rescue Dossier →